{"id":"NCT03137121","sponsor":"University of Alabama at Birmingham","briefTitle":"Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients","officialTitle":"Olanzapine for the Treatment of Chronic Nausea and/or Vomiting, Unrelated to Chemotherapy or Radiation, in Advanced Cancer Patient - A Pilot, Dose-Finding Trial","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2017-07-12","primaryCompletion":"2019-07-12","completion":"2020-09-15","firstPosted":"2017-05-02","resultsPosted":"2021-08-17","lastUpdate":"2021-08-17"},"enrollment":30,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Advanced Cancer"],"interventions":[{"type":"DRUG","name":"Olanzapine","otherNames":["Zyprexa"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Olanzapine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the use of olanzapine for the treatment of cancer patients with chronic nausea and/or vomiting unrelated to chemotherapy or radiation in a randomized placebo-controlled pilot trial.","primaryOutcome":{"measure":"Mean Nausea Scores","timeFrame":"Nausea score from the Visual Analogue Scale will be recorded each day daily for 7 days. An average value calculated will be reported for the 7 day period.","effectByArm":[{"arm":"Olanzapine","deltaMin":1,"sd":1},{"arm":"Placebo","deltaMin":9,"sd":2}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":10},"locations":{"siteCount":5,"countries":["United States"]},"refs":{"pmids":["32379269"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":15},"commonTop":["Nausea"]}}